Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
about
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesisExploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literatureClinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinomaCurrent and emerging therapies in unresectable and recurrent gastric cancerRamucirumabTaxanes in the Treatment of Advanced Gastric CancerEmerging therapeutic targets in esophageal adenocarcinomaPerioperative and Palliative Chemotherapy for Esophageal CancerDoublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled TrialsTargeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI InhibitorsAdvanced gastric cancer: Current treatment landscape and future perspectivesNovel targets in the treatment of advanced gastric cancer: a perspective reviewCurrent Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical ApplicationNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialVEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedsideChemotherapy in Elderly Patients with Gastric CancerTargeted therapy for advanced gastric cancer: A review of current status and future prospectsChanging strategies for target therapy in gastric cancerPersonalized medicine in gastric cancer: Where are we and where are we going?Advanced gastric cancer: What we know and what we still have to learnAngiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Clinical significance of MET in gastric cancerGastric cancer: The times they are a-changin'Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological featuresSignet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challengeRamucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinomaSecond-line treatment of metastatic gastric cancer: Current options and future directionsMolecular Dimensions of Gastric Cancer: Translational and Clinical PerspectivesCompanion diagnostics for the targeted therapy of gastric cancerNeoadjuvant therapy for gastric cancer: current evidence and future directionsClinical utility of ramucirumab in advanced gastric cancerRamucirumab: A New Therapy for Advanced Gastric CancerChemotherapy beyond second-line in advanced gastric cancerOptimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysisMolecular classification of gastric cancer: Towards a pathway-driven targeted therapyCritical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancersStrategies and Advancements in Harnessing the Immune System for Gastric Cancer ImmunotherapyNext-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityGastric Cancer: New Drugs - New StrategiesBeyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers
P2860
Q26740812-8AF1D275-8136-4BB4-BA48-33E29FEB2BA7Q26741242-BEC20490-78D9-4AB5-B82A-551BF4656125Q26741530-0BB27F18-B6DB-42D0-B8F7-B9B4759DF069Q26745453-AD9EFD33-EF52-4154-A357-0C3C49ED101CQ26747347-8B71CC00-4E7A-4BFC-A31D-04E284409D3EQ26747708-91E894BC-73C9-41D6-ACF5-75F69F5BF06BQ26751209-263AB1EE-9335-4D21-89CB-C501F61F0072Q26753865-AD692820-B787-44A5-BBE6-2688DEAA84D3Q26764802-4DDCBD08-302E-458C-BCDE-70BBB8C255BDQ26764892-0B410FDE-75A8-4116-BD06-519D7B8589B0Q26764934-647AA794-DAE1-4F6E-A13A-A0A5FEE94341Q26765208-2F4FF558-DE47-41C7-9F69-8A1AE7FB0296Q26765941-4A5ACB9B-D7F1-4963-A31B-D6DD94B1EAAFQ26769884-D21687BA-9957-4D28-81E1-0039EF8909CCQ26770678-09781B19-6D7D-4735-AD43-1129A8AD95BFQ26771424-EA9F9B9C-D2DD-4F25-9852-A68A25B3B2DBQ26774138-16A0FDD7-84BC-429C-96D3-E16DD1E36439Q26774513-3836C626-5314-4735-82AD-B5C117E538BFQ26774521-0AD63F15-8128-4272-90D3-6AF953AB6F65Q26774528-083F1926-23D6-4AF7-A1A8-FFFD7E944AD8Q26775394-9393138D-02F4-45E4-A318-57FA7F8AFCF9Q26776190-100DA500-486B-469D-9107-967B6A911555Q26776195-4B91D801-06EA-426E-BCD8-8A19207505CDQ26776198-1B4411B0-E76B-4D71-B1E5-CF8900BB3679Q26777538-95DFEAC0-7A85-49AF-BE1B-4B0E177D57E9Q26777690-12936832-D473-4673-9F71-004EC334732FQ26778027-D446A978-D56D-4077-AC5B-A05240AE733AQ26779725-50D58F05-4D66-4905-9C17-B54A993A7AC2Q26780298-D791050B-0486-4366-BBD7-8C94498EE6C0Q26781043-9E3AD2FA-D767-44E9-A319-351FBC0F1B54Q26785665-D0031012-1CB8-445E-AC79-8A2A1617C35EQ26785706-729B71E6-E898-47BB-878C-D996094E4C2CQ26798288-0C2EB0C8-616A-4BD5-89E9-070B029A798CQ26798400-803B87CE-21B5-4F04-8172-1A6196402240Q26798420-2953B2FA-ECEE-4FF3-988F-050299895E27Q26801289-03832596-1975-4FE6-8438-CCD38C1D122FQ26823515-B376D1AF-68DD-40F9-B169-5350589764C4Q26992272-52B993B4-504A-4095-9F60-A2085F04DF17Q27028079-8F3030F7-4DE9-4C26-8D96-62224EA2B0D9Q28066550-00F331CD-11F8-4893-AFDE-0F9101203B0D
P2860
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Ramucirumab plus paclitaxel ve ...... lind, randomised phase 3 trial
@ast
Ramucirumab plus paclitaxel ve ...... lind, randomised phase 3 trial
@en
type
label
Ramucirumab plus paclitaxel ve ...... lind, randomised phase 3 trial
@ast
Ramucirumab plus paclitaxel ve ...... lind, randomised phase 3 trial
@en
prefLabel
Ramucirumab plus paclitaxel ve ...... lind, randomised phase 3 trial
@ast
Ramucirumab plus paclitaxel ve ...... lind, randomised phase 3 trial
@en
P2093
P921
P3181
P1433
P1476
Ramucirumab plus paclitaxel ve ...... lind, randomised phase 3 trial
@en
P2093
Atsushi Ohtsu
David Ferry
Eric Van Cutsem
György Bodoky
Hansjochen Wilke
Jonathan D Schwartz
Kumari Chandrawansa
Michael Emig
Naotoshi Sugimoto
P304
P3181
P356
10.1016/S1470-2045(14)70420-6
P407
P577
2014-09-17T00:00:00Z